Business Context and Reporting Period
Company: Cyclerion Therapeutics, Inc. (CYCN)
Filing Type: Form 8-K (Current Report)
Date of Report: April 1, 2026
Event: Entry into a Material Definitive Agreement (Merger) with Korsana Biosciences, Inc.
Cyclerion has entered into an Agreement and Plan of Merger to acquire Korsana Biosciences, Inc. The transaction involves a reverse merger structure where Korsana will become a wholly-owned subsidiary of Cyclerion, followed by a consolidation into a Cyclerion subsidiary. The combined entity will be renamed Korsana Biosciences, Inc., and Cyclerion will redomicile from Massachusetts to a jurisdiction determined by Korsana.
Key Financial Metrics and Transaction Terms
- Financing (PIPE): Korsana has secured a private placement of approximately $380 million from institutional and accredited investors in PIPE Securities (common stock and pre-funded warrants).
- Pro Forma Ownership: Pre-Merger Korsana stockholders will own approximately 1.5% of the combined company; pre-Merger Cyclerion shareholders will own approximately 98.5%.
- Exchange Ratio: Based on a formula considering fully-diluted shares and Cyclerion's net cash at closing. The ratio adjusts if Cyclerion net cash is less than or greater than $0.
- Beneficial Ownership Limitation: Initially set at 14.99%. Shares exceeding this limit will be converted into pre-funded warrants.
- Contingent Value Rights (CVRs): Pre-Merger Cyclerion shareholders will receive one CVR per share held. These rights entitle holders to net proceeds from the disposition of Cyclerion's legacy assets (including the Akebia Therapeutics license and Tisento Therapeutics holdings) over a period of up to 15 years.
- Executive Compensation: CEO Regina Graul is eligible for a change-of-control bonus of up to $150,000, plus severance and equity acceleration upon termination without cause or for Good Reason.
Material Changes and Corporate Actions
- Corporate Name Change: Cyclerion Therapeutics, Inc. will change its name to Korsana Biosciences, Inc.
- Reverse Stock Split: Cyclerion will effect a reverse stock split of its common stock (specific ratio not detailed in this filing).
- Board Composition: Upon closing, the Board will consist of six members, all designated by Korsana. The combined company will be led by Korsana's President and CEO.
- Equity Adjustments:
- Cyclerion equity awards will have vesting accelerated prior to closing.
- Out-of-the-money Cyclerion options will be cancelled.
- In-the-money Cyclerion options will be cancelled and converted to cash payments based on the "Parent Closing Price."
- Korsana equity awards (options, RSUs, warrants) will be assumed by Cyclerion.
- Series B Preferred Stock: A new class of non-voting convertible preferred stock will be created for holders of Korsana Series Seed Preferred Stock. Holders of this stock (if 30% remains outstanding) will have the right to elect four directors.
Guidance, Outlook, Risks, and Contingencies
Expected Closing: The transaction is expected to close in the third quarter of 2026.
Conditions to Closing:
- Approval by Cyclerion and Korsana shareholders.
- Nasdaq listing approval for the combined company.
- Effectiveness of the Form S-4 registration statement.
- Expiration of HSR Act waiting periods.
- Receipt of at least $150 million in the financing transaction (though $380 million is targeted).
Risks and Contingencies:
- Termination Fees: The Merger Agreement includes termination fees payable by either party under specified circumstances.
- CVR Uncertainty: There is no assurance that Cyclerion shareholders will receive any payments from the CVRs if legacy assets are not sold or monetized.
- Forward-Looking Statements: Risks include failure to obtain regulatory approvals, inability to complete financing, delays in closing, and the combined company's ability to manage expenses and advance product candidates.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and the final Exchange Ratio once the Form S-4 is filed.
- Confirm the valuation implied by the 1.5% ownership stake for Korsana shareholders relative to the $380 million PIPE investment.
- Review the Form S-4 for detailed terms regarding the CVR Agreement, specifically the definition of "legacy assets" and the timeline for potential payouts.
- Monitor the shareholder vote results for both Cyclerion and Korsana, noting that significant support agreements (43.9% of Korsana and 24.2% of Cyclerion) are already in place.
- Assess the liquidity impact of the $380 million PIPE on the combined company's runway for clinical development.